Phospholipase A2 inhibitors in inflammation

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 7, 2001, Pages 1123-1136

  Lehr, M ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Asthma; Inflammation; Inhibitors; Neurodegenerative diseases; Phospholipase A2; Septic shock

Indexed keywords

2 (HEXADECYLTHIO)BENZOIC ACID; 2 DIETHYLAMINO 2 OXOETHYL ESTER; 2 INDOLECARBOXYLIC ACID; 2 MORPHOLINOETHYL ESTER; 9,10 DIHYDRO 9,10 ETHANOANTHRACENE DERIVATIVE; ACETAMIDE DERIVATIVE; ANTHRACENE DERIVATIVE; ARACHIDONIC ACID; ARYLSULFONAMIDE; BENZOIC ACID DERIVATIVE; CARBAZOLE DERIVATIVE; ESTER DERIVATIVE; INDOLE DERIVATIVE; INDOLEACETIC ACID; LEUKOTRIENE; LY 311727; LYSOPHOSPHOLIPID; MEMBRANE PHOSPHOLIPID; OXAMETACIN; OXIME DERIVATIVE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PROSTAGLANDIN; PYRAZOLE DERIVATIVE; SULFONAMIDE; SULFONIC ACID DERIVATIVE; SULFONYLAMINOPYRAZOLE DERIVATIVE; TETRONIC ACID DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREIDOINDOLE; VARESPLADIB;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ASTHMA; BIOCHEMISTRY; BRONCHITIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIGESTIVE SYSTEM INFLAMMATION; DRUG STRUCTURE; ENZYME ACTIVATION; IN VITRO STUDY; INFLAMMATION; LUNG DISEASE; MAMMAL; MOUSE; NONHUMAN; OSTEOARTHRITIS; PAIN; PANCREATITIS; PATENT; PATHOPHYSIOLOGY; PSORIASIS; RAT; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; SKIN INFLAMMATION; TREATMENT INDICATION; ULCERATIVE COLITIS;

EID: 0034944125     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.7.1123     Document Type: Review

References (78)

1. Lipid mediator network in cell signalling: Update and impact of cytokines
2. Lysophosphatidylcholine (LPC) induces pro-inflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism
3. Intracutaneous injection of lysophosphatidylcholine induces skin inflammation and accumulation of leukocytes
4. 2
5. 2
6. 2 inhibitors in development
7. 2 inhibitors
8. 2 in vitro and in vivo by several novel series of inhibitor compounds
9. 2
10. 2 from human synovial fluid in rheumatoid arthritis
11. 2 present in rheumatoid arthritic synovial fluid
12. 2 from the human monocytic cell line U937
13. 2 from rat kidney activated at physiological calcium concentrations
14. 2 enzymes: Classification and characterization
15. 2
16. 2: Structure and function
17. 2(s); comparison of arachidonyl-selective and -nonselective enzymes
18. 2 is coupled to hormonally regulated release of arachidonic acid
19. 2 in allergic response and parturition
20. 2
21. 2 regulation
22. 2 gene in inbred mouse strains
23. 2 generation in mouse bone marrow-derived mast cells
24. 2 inhibitors
25. 2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate
26. 2 lacks edema producing activity in rat
27. 2
28. 2 but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells
29. 2
30. 2
31. 2
32. 2
33. 2 induced prominent release of arachidonic acid from human myeloid leukemia cells
34. 2 receptor
35. 2 using radioactive substrate
36. 2 and investigations by NMR and molecular modeling into the binding interactions in the enzyme-inhibitor complex
37. 2 with antiinflammatory activity
38. 2s
39. 2 is a 100-kDa protein in human monoblast U937 cells
40. 2 using pyrene-labeled phospholipids in the presence of serum albumin
41. 2
42. 2
43. 2
44. 2 on short chain phosphatidylcholine-mixed micelles: Development of a spectrophotometric assay suitable for a microtiterplate reader
45. 2
46. 2 isozymes
47. 2: Structure-function studies with vesicle, micelle, and membrane assays
48. 2 at the lipid-water interface by choline derivatives that partially partition into the phospholipid bilayer
49. 2 activity in vitro and in vivo
50. 2 inhibitor, blocks the mobilization of arachidonic acid in human platelets and neutrophils
51. 2 inhibitors using bovine platelets and HPLC with UV-detection
52. 2-mediated arachidonic acid release by several indole-2-carboxylic acids and 3-(pyrrol-2-yl)propionic acids in bovine and in human platelets
53. 2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets
54. 2
55. 2. Part 2: Synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'
56. 2)
57. 1 cells
58. 2 in phorbol ester (TPA)-induced arachidonic acid liberation in bovine platelets
59. 2 activation
60. Surfactant-induced cell toxicity and cell lysis. A study using B16 melanoma cells
61. 2
62. 2 inhibitors, arachidonyltrifluoromethyl ketone, methyl arachidonylfluorophosphonate and palmityltrifluoromethyl ketone
63. 2 inhibitors
64. 2
65. 2, on carrageenan-induced rat paw edema, phorbolester-induced mouse ear edema and in a sheep model of asthma
66. 2 inhibitors upon oral, intra peritoneal and dermal administration
67. 2
68. 2 enzyme activity and immunoreactivity in a prospective analysis of patients with septic shock
69. 2 is induced in reactive glia following different forms of neurodegeneration
70. 2) immunoreactivity is elevated in Alzheimer's disease brain
71. 2
72. 2 inhibitor: A new class of anti-inflammatory drugs, SPI
73. 2
74. 2-independent mechanisms
75. 2 activity and gene expression are stimulated by tumor necrosis factor: Dexamethasone blocks the induced synthesis
76. 2 and cyclooxygenase-2
77. 2
78. 2 reveals a novel topology and catalytic mechanism